The prostate cancer market is expected to experience a moderate growth between 2016 and 2026. The main drivers of growth will be the expected label expansion of secondgeneration hormonal agents into hormonesensitive disease and nonmetastatic castration resistant prostate cancer nmCRPC, and the launch and uptake of nine new premiumpriced therapies.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/pharmapointprostate-cancer-drug-forecast-market-91

Until now, the hormone sensitive setting has been dominated by the use of cheap firstgeneration hormonal agents, with the use of premiumpriced secondgeneration hormonal agents Xtandi and Zytiga limited to metastatic CRPC. The prostate cancer competitive landscape is going to experience a substantial change. Given that Zytiga and Xtandi are limited by the insurgence of acquired resistance, physicians will face the critical issue of determining the best treatment sequence for subsequent lines of therapy, most notably in the mCRPC setting. Additionally, companies are now moving toward a more personalized approach in prostate cancer, targeting mCRPC patients with specific genetic signatures, such as PTEN loss and DNA repair abnormalities. GlobalData expects these biomarkerdriven drug development strategies to induce further patient stratification and to add complexity to the CRPC treatment algorithm.

Scope

• Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
• Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
• Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to

• Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/pharmapointprostate-cancer-drug-forecast-market-91

Table of content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 11
2 Prostate Cancer: Executive Summary 13
2.1 Value of Prostate Cancer Market to Increase TwoFold By 2026 14
2.2 Xtandi to Become the Undisputed Leader in the Global Prostate Cancer Market 16
2.3 Prostate Cancer Treatment Landscape to Undergo Dramatic Change 18
2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine 18
2.5 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response 20
2.6 What Do the Physicians Think? 20
3 Introduction 23
3.1 Catalyst 23
3.2 Related Reports 24
3.3 Upcoming Related Reports 24
4 Disease Overview 25
4.1 Etiology and Pathophysiology 25
4.1.1 Etiology 25
4.1.2 Pathophysiology 26
4.1.3 Biomarkers 27
4.2 Classification or Staging Systems 29
4.3 Symptoms 31
4.4 Prognosis 31
4.5 Quality of Life 31
5 Epidemiology 33
5.1 Disease Background 33
5.2 Risk Factors and Comorbidities 33
5.3 Global and Historical Trends 35
5.3.1 US 36
5.3.2 5EU 37
5.3.3 Japan 37
5.4 Forecast Methodology 37
5.4.1 Sources Used 38
5.4.2 Forecast Assumptions and Methods 43
5.5 Epidemiological Forecast for Prostate Cancer 20162026 52
5.5.1 Diagnosed Incident Cases of Prostate Cancer 52
5.5.2 AgeSpecific Incident Cases of Prostate Cancer 53
5.5.3 Incident Cases by Stage at Diagnosis 54
5.5.4 Incident Cases by Risk of Biochemical Recurrence 55
5.5.5 10Year Diagnosed Prevalent Cases of Prostate Cancer 56
5.5.6 10Year Prevalent CRPC Cases 57
5.5.7 10Year Prevalent Metas

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/pharmapointprostate-cancer-drug-forecast-market-91

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports